Celgene Corp. buy tamam
Start price
10.09.15
/
50%
€108.55
Target price
21.07.16
€117.26
Performance (%)
-13.06%
End price
21.07.16
€94.37
Summary
This prediction ended on 21.07.16 with a price of €94.37. The prediction for Celgene Corp. disappointed with a performance of -13.06%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% | 69.888% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% | 101.814% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% | 45.300% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% | 63.763% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene: Time To Buy The Dip
The biotech sector has been hit hard in the recent sell-off in the overall markets. Major indices are down some 15% from recent highs; squarely in the correction territory.
The negative sentiment on this high beta sector of the market could last a while longer, but it is not too soon to start to accumulate the high quality names.
One of these is Celgene, which is down more than $20 a share from recent highs and offers a compelling combination of growth and value at these levels.
(Laufzeit überschritten)